Lymphoma

In this video, Jing-Zhou Hou, MD, PhD, medical oncologist and hematologist, clinical instructor and co-chair of the hematological malignancies program at UPMC Hillman Cancer Center, discussed therapeutic options for hard to treat lymphoma.

In this video, Jing-Zhou Hou, MD, PhD, medical oncologist and hematologist, clinical instructor and co-chair of the hematological malignancies program at UPMC Hillman Cancer Center, discussed advancements in molecular targets in lymphoma.

The FDA granted accelerated approval to glofitamab-gxbm for treatment of certain adults with relapsed or refractory diffuse large B-cell lymphoma.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses mantle cell lymphoma research presented at ASCO Annual Meeting.

CHICAGO — Radiation therapy can be safely omitted for patients with primary mediastinal B-cell lymphoma who demonstrate a complete metabolic response after chemoimmunotherapy, according to data presented at ASCO Annual Meeting.

CHICAGO — A split-dose approach to the standard R-CHOP chemotherapy regimen resulted in a 71% complete response rate among older adults with newly diagnosed diffuse large B-cell lymphoma, results from a phase 2 study showed.

CHICAGO — Second-line therapy with axicabtagene ciloleucel conferred a significant increase in OS compared with the current standard of care among adults with relapsed or refractory large B-cell lymphoma, results of the randomized phase 3 ZUMA-7 study showed.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses recent FDA approvals in Lymphoma treatment and care.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute discusses factors that may keep patients from necessary DLBCL care.

In this video interview, Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute emphasizes need for consistent type of care of DLBCL patients who do not go into remission.